Latest Headlines

Latest Headlines

GlaxoSmithKline's nicotine franchise pairs up with smoking cessation app

In a twist on the traditional smoking cessation model, GlaxoSmithKline is pairing with 2morrow's SmartQuit app to supply patches to smokers who have already completed the app plan.

Adherium wins approval to sell its 'smart' inhaler devices in Canada

Australia's Adherium Group announced clearance to sell its SmartTurbo and SmartTouch "smart inhaler" devices in Canada. They improve adherence by tracking usage and sending reminders.

GSK supercharges R&D; for miniaturized bioelectronic nerve implant for chronic disease

Already a growing presence in bioelectronics, GlaxoSmithKline is taking its efforts to the next level with plans to roll out implantable devices that send electric pulses to treat certain chronic diseases.

GSK's Witty hears the rhythm in China's drumbeat for lower prices

A drumbeat of policy steps and guidance from China so far this year has made it more than clear the country intends to buy, make and prescribe drugs in drastically new ways and at lower costs--and that should ring a bell for earlier insight along those lines by GlaxoSmithKline CEO Andrew Witty.

GlaxoSmithKline dumps Five Prime's cancer drug in the midst of Phase I

GlaxoSmithKline is cutting ties with Five Prime Therapeutics' in-development cancer therapy, backing out in the middle of a mesothelioma trial.

Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK

Novartis has stopped a Phase III trial of Genmab's Arzerra in pemphigus vulgaris patients. The decision, which comes 7 months after Novartis agreed to buy the rights to Arzerra in autoimmune indications from GlaxoSmithKline, will result in a focusing of attention on the testing of the monoclonal antibody as a treatment for relapsing multiple sclerosis.

GSK extends business process analytics contract to 2020

GlaxoSmithKline has renewed its contract with business process management company WNS. The extension of the relationship means GSK will continue to rely on WNS for research and analytics services until at least December 2020.

U.K. rejects petition demanding meningitis B vaccine for all children

The U.K. rolled out its meningitis B vaccination program for babies in September, but a petition demanding that it be expanded for all children quickly gathered steam. The Department of Health rejected the petition on Wednesday, saying that offering the jab to all children would not be cost-effective.

U.S. Army, GSK's P. vivax malaria vaccine fails to protect in early trial

A vaccine developed in collaboration between GlaxoSmithKline and the U.S. Army failed to protect subjects in an early trial against the world's most prevalent malaria parasite. Researchers will press forward, however, saying the knowledge gained may assist future development.

GlaxoSmithKline scouts for candidates to replace CEO Andrew Witty

GlaxoSmithKline is casting about for a new CEO. Amid shareholder pressure for a breakup or shake-up or both, the company reportedly has asked its headhunting firm to put together a short list of candidates to replace current chief Andrew Witty.